S*BIO of Singapore Sells Cancer Drug Rights to MEI Pharma
04:58 EDT 11 Aug 2012 | ChinaBio Today
S*BIO of Singapore has sold worldwide rights for a clinical stage oncology drug to MEI Pharma of San Diego. Pracinostat is an oral histone deacetylase (HDAC) inhibitor. The drug has completed Phase II clinical trials in patients with hematologic d..
Original Article: S*BIO of Singapore Sells Cancer Drug Rights to MEI Pharma
More From BioPortfolio on "S*BIO of Singapore Sells Cancer Drug Rights to MEI Pharma"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
